Alumis Inc. - Common Stock (NQ:ALMS)

6.850 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alumis Inc. - Common Stock

< Previous 1 2 3 Next >

Top movers in Friday's session ↗

March 28, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 25, 2025

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

What's Going On With Alumis Shares Tuesday? ↗

March 25, 2025

Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.

Via Benzinga

Which stocks are moving before the opening bell on Tuesday? ↗

March 25, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

ALMS Stock Earnings: Alumis Reported Results for Q2 2024 ↗

August 15, 2024

Alumis just reported results for the second quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 25, 2025

Via Benzinga

Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday ↗

March 20, 2025

Via Benzinga

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

March 04, 2025

From ACELYRIN, INC.

Via GlobeNewswire

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

March 04, 2025

From ACELYRIN, INC.

Via GlobeNewswire

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

February 20, 2025

From ACELYRIN, INC.

Via GlobeNewswire

What's going on in today's pre-market session ↗

February 07, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 07, 2025

Via Benzinga

ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders

February 06, 2025

From Halper Sadeh LLC

Via Business Wire

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

February 06, 2025

From ACELYRIN, INC.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 24, 2025

Via Benzinga

JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 17, 2025

Via Benzinga

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

December 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 19, 2024

Via Benzinga

Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday ↗

November 19, 2024

Via Benzinga

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 31, 2024

Via Benzinga

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside ↗

October 17, 2024

HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers...

Via Benzinga

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 17, 2024

Via Benzinga

Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' ↗

October 09, 2024

Target (TGT) stock recommended by Jim Cramer at current price with plans to buy more. Merck (MRK) and Unity Software (U) also discussed.

Via Benzinga

Topics Artificial Intelligence

Alumis to Participate in Upcoming September Investor Conferences

September 03, 2024

From Alumis Inc.

Via GlobeNewswire

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

August 13, 2024

From Alumis Inc.

Via GlobeNewswire

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

July 29, 2024

From Alumis Inc.

Via GlobeNewswire

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation ↗

July 24, 2024

Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK...

Via Benzinga

Ardent Health Slips After Downsized IPO ↗

July 21, 2024

Shares of Ardent Health slipped in their trading debut on Thursday after the hospital operator reduced its initial public offering from its proposed size and priced below the marketed range.

Via Talk Markets

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering ↗

June 28, 2024

Alumis priced its IPO at $16/share, raising $210 million with 13.13 million shares. Trading begins June 28, 2024. Alumis develops oral therapies for immune-mediated diseases, with its lead candidate...

Via Benzinga

Topics Initial Public Offering

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.